Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study

Affiliation auteurs!!!! Error affiliation !!!!
TitrePrognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study
Type de publicationJournal Article
Year of Publication2017
AuteursCadranel J, Quoix E, Duruisseaux M, Friard S, Wislez M, Danie C, Fabre E, Madroszyk A, Westeel V, Merle P, Lena H, Dansin E, Mazieres J, Scherperee A, Hiret S, Kaderbhai C, Souquet P-J, Missy P, Langlais A, Morin F, Zalcman G, Moro-Sibilot D, Barlesi F
JournalJOURNAL OF THORACIC ONCOLOGY
Volume12
PaginationS957-S958
Date PublishedJAN
Type of ArticleMeeting Abstract
ISSN1556-0864
Mots-clésBevacizumab, EGFR, KRAS, non-small cell lung cancer (NSCLC)
DOI10.1016/j.jtho.2016.11.1318